ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 225,25
0,46%
Dow Jones
39 464,93
0,20%
DAX
18 771,21
0,49%
Brent Oil
83,54
-0,49%
Bitcoin
60 758,03
-3,63%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) Actualités

ATNM Actinium Pharmaceuticals Inc

8,7585
-0,1415 (-1,59%)
Dernière mise à jour : 16:51:52
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Actinium Pharmaceuticals Inc ATNM AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,1415 -1,59% 8,7585 16:51:52
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,91 8,40 9,00 8,90
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/5/202414:00PRNUSActinium Announces KOL Webinar to Highlight Recently..
18/4/202414:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
01/4/202414:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
26/3/202412:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
11/3/202412:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
26/2/202413:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
23/2/202413:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
09/2/202422:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/2/202423:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/1/202413:30PRNUSActinium Announces Acceptance of Five Abstracts for..
29/12/202323:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202314:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
11/12/202313:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
08/12/202314:00PRNUSActinium to Highlight Broad Potential of Targeted..
01/12/202323:00EDGAR2Form 8-K - Current report
09/11/202323:05EDGAR2Form DEF 14A - Other definitive proxy statements
06/11/202313:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
02/11/202321:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
02/11/202314:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202314:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
04/10/202313:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
27/9/202315:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
07/9/202314:40PRNUSActinium Pharma Presents Survival Data from Extended..
31/8/202313:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
21/8/202313:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
14/8/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:00EDGAR2Form S-3 - Registration statement under Securities Act of..
24/7/202313:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
26/6/202313:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
23/6/202314:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
16/6/202313:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
14/6/202313:00PRNUSActinium Pharma to Present at the TD Cowen..
12/6/202313:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
07/6/202313:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
22/5/202313:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
11/5/202317:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..

Dernières Valeurs Consultées

AMEX
ATNM
Actinium Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés